Sensorion
Montpellier, FR· latest recorded location
SENSORION is named on 6 US grants and 12 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 6
- Published applications
- 12
- Inventors
- 15
- Granted in 2026 so far
- 1
- Most recent grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 3 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 18 documents
Recent patents
- Calcineurin inhibitors of the setron family for the treatment of hearing loss11 Aug 2026US 12,702,671 B2
- (+)-azasetron for use in the treatment of ear disorders28 Mar 2023US 11,612,605 B2
- Calcineurin inhibitors of the setron family for the treatment of hearing loss6 Sep 2022US 11,433,077 B2
- Synthesis of 4-aminopyrimidine compounds23 Nov 2021US 11,180,480 B2
- Calcineurin inhibitors for use in the treatment of lesional vestibular disorders29 Jan 2019US 10,188,695 B2
- Mini syringe driver30 Jul 2026US 2026/0216442 A1
- Regulatory sequences comprising microrna target sites8 Jan 2026US 2026/0009028 A1
- Azasetron for the treatment of sudden sensorineural hearing loss29 May 2025US 2025/0170139 A1
- Method of preventing cochlear disease, disorder or condition using (+)-azasetron20 Jul 2023US 2023/0226071 A1
- Calcineurin inhibitors of the setron family for the treatment of hearing loss8 Dec 2022US 2022/0387438 A1
Most cited
By later US patents